Progress and Prognosis According to the Care Cascade in Patients Who Are Anti-HCV Positive

doi:10.21203/rs.3.rs-1430773/v1

Download PDF

Research Article

Progress and Prognosis According to the Care Cascade in Patients Who Are Anti-HCV Positive

https://doi.org/10.21203/rs.3.rs-1430773/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 11 Apr, 2023

Read the published version in BMC Gastroenterology →

You are reading this latest preprint version

Background

Few studies have analyzed the frequency of HCV RNA testing and actual treatment among anti-HCV positive patients in Korea, which has a low prevalence of HCV infection. This study aimed to analyze the diagnosis process, treatment results, and prognosis according to care cascade in patients who are anti-HCV positive.

Methods

3,253 anti-HCV positive patients presented to a tertiary hospital between January 2005 and December 2020. The number of patients who underwent HCV RNA testing, treatment, and proportion of sustained virologic response (SVR) according to the type of antivirals was investigated. We investigated the cumulative incidence of hepatocellular carcinoma (HCC) and liver cirrhosis.

Results

Of a total of 3,253 people, 1,177 (36.2%) underwent HCV RNA testing and 858 (72.9%) were positive for HCV RNA. 494 (57.6%) patients received antiviral treatment, and 443 (89.7%) experienced SVR without significant differences according to the type of antivirals. Of the 421 treated patients, 16 (14.2%) developed HCC. The cumulative incidence of HCC at 15 years was significantly different according to the presence of liver cirrhosis (10/83, 29.5% vs. 6/338, 10.8%, p < 0.001). The cumulative incidences of HCC or liver cirrhosis did not show significant differences according to the presence of SVR₁₂ (14/388, 13.2% vs. 2/33, 52.5%, p = 0.084, 21/319, 15.0%, vs. 3/22, 28.7%, p = 0.051).

Conclusions

Owing to the introduction of direct-acting antivirals, high SVR₁₂ was achieved, but the proportion of anti-HCV positive patients who received HCV RNA testing and treatment was not high. HCC surveillance after SVR₁₂ is recommended for chronic hepatitis C patients with cirrhosis.

hepatitis C virus

sustained virologic response

liver cirrhosis

hepatocellular carcinoma

The current prevalence of chronic hepatitis C in Korea is estimated to be approximately 0.6 to 0.8%.¹ Among Korean patients afflicted with hepatitis C, genotype 1b and 2 are the most common types.¹ Overall sustained virologic response rate at 12 weeks (SVR₁₂) has improved significantly since the treatment regimen of hepatitis C was switched from interferon drugs to direct-acting antivirals (DAAs), and the efficacy of DAA combination therapy has become more potent. Moreover, DAAs that can treat pangenotypes such as glecaprevir/pibrentasvir (G/P) have been introduced.² Nevertheless, patients with chronic hepatitis C often experience DAA treatment failure in the real world. Factors associated with the failure of DAAs include the genetic subtype of chronic hepatitis C, hepatitis C virus (HCV) resistance-associated substitution, liver cirrhosis, a history of previous hepatitis C treatment failure, old age, decreased liver function, and decreased renal function.³ Furthermore, eradication of HCV by antiviral treatment does not mean that the risk of hepatocellular carcinoma (HCC) is completely eliminated. In particular, patients with advanced fibrosis (F3) or cirrhosis (F4) have a substantial residual risk of HCC, and surveillance is required.⁴

It is known that HCC can occur after SVR in the liver of advanced fibrosis (F3). Therefore, early diagnosis and treatment of chronic hepatitis C through a surveillance program is important. Few studies have analyzed the frequency of HCV ribonucleic acid (RNA) testing among patients who are anti-HCV positive at a tertiary hospital and the proportion of patients who receive HCV treatment in real practice. Therefore, this study aimed to analyze the diagnosis process, treatment results, and prognosis of chronic hepatitis C through a complete investigation of anti-HCV positive patients from January 2005 to December 2020 at a tertiary hospital.

Study population

This retrospective cohort study used data from a single tertiary hospital recorded between January 2005 and December 2020. Patients who were anti-HCV positive and visited a single tertiary academic institution (Gangnam Severance Hospital) during the study period were included. HCV genotyping and serum HCV RNA quantification were performed.

The exclusion criteria were as follows: (1) previous history of HCC or HCC diagnosis within 6 months after HCV treatment, (2) previous history of hepatic decompensation or decompensation development within 6 months after HCV treatment, (3) liver transplant status or transplantation within 6 months after HCV treatment, (4) heavy alcohol consumption, (5) toxic hepatitis, and (6) follow-up period less than 6 months.

The study protocol was performed in accordance with the principles of the 1975 Declaration of Helsinki, and approved by the Yonsei University Gangnam Severance Hospital, Institutional Review Board (3-2021-0255). The need for informed consent was waived by the ethics committee/Institutional Review Board of Yonsei University Gangnam Severance Hospital, because of the retrospective nature of the study.

Baseline workup and treatment plan

HCV antibody examination was performed at baseline visits as part of the study enrollment process. Next, those who were anti-HCV positive underwent HCV RNA quantification to confirm HCV infection and HCV genotyping. In patients who were HCV RNA negative, past HCV infection and false-positive results for anti-HCV were distinguished using the recombinant immunoblot assay (RIBA) test.

Patients who were confirmed to be HCV RNA positive were started on hepatitis C treatment. HCV treatment is largely divided into interferon-based treatment that stimulates the immune response to HCV and DAA therapy, which directly inhibits the protein components of the HCV. For DAAs, daclatasvir/asunaprevir (DCV/ASV), ledipasvir/sofosbuvir (LED/SOF), sofosbuvir (SOF) and ribavirin, elbasvir/grazoprevir (EBR/GZR), ombitasvir/paritaprevir/ritonavir (OBV/PTV/r), and more recently, the pangenotype agent glecaprevir/pibrentasvir (G/P) were used. The treatment period varied from 8 to 12 weeks, depending on the genotype and presence of cirrhosis. Patients’ HCV RNA was analyzed 4 weeks after the initiation of treatment to confirm patient compliance and evaluate drug according to treatment response, as well as at the end of treatment to evaluate the response at the end of treatment. Moreover, the overall rate of SVR 12 or 24 weeks after completion of therapy (SVR₁₂or SVR₂₄) was investigated for all types of HCV treatment. After completion of treatment, each patient underwent abdominal ultrasonography for the surveillance of HCC and fibrosis progression, and the cumulative incidence of HCC and liver cirrhosis was investigated according to SVR₁₂orSVR₂₄, baseline liver cirrhosis.

Laboratory assay

HCV genotyping was performed using the restriction fragment mass polymorphism method.

Serum HCV RNA quantification (lower limit of quantification, 15 IU/mL) was performed with a Cobas 4800 system (Roche Diagnostics GmbH, Mannheim, Germany), which consists of a Cobas x480 instrument and a Cobas z480 analyzer, to confirm the sustained virological response before and after treatment. In addition, the RIBA test was performed with samples that were HCV RNA negative using MP Diagnostics HCV Blot 3.0 (MP Biomedicals, Singapore).

Diagnosis of hepatocellular carcinoma and liver cirrhosis

HCC diagnosis was based on the guidelines of the Korean Liver Cancer Association-National Cancer Center.⁵ HCC was diagnosed when typical radiologic features such as hypervascularity on arterial phase and washout on portal venous or delayed phase were detected by four-phase multi-detector computed tomography or dynamic contrast-enhanced magnetic resonance imaging. When the diagnosis of HCC was uncertain, it was finally confirmed using two imaging modalities or a liver biopsy.⁶

Liver cirrhosis was defined by ultrasonography (US) features such as a blunted, nodular liver surface accompanied by splenomegaly (>12 cm), in accordance with previous studies.^{7, 8}

Statistical analysis

Patients’ baseline characteristics were expressed as mean with standard deviation in the case of continuous variables and numbers with percentages in the case of categorical variables. Student’s t-test was used to compare continuous variables, while Fisher’s exact tests or chi-squared test were used to compare categorical variables. The cumulative incidence rates of HCC and liver cirrhosis were investigated using the Kaplan–Meier method and compared by the log-rank test. Data of patients with HCC or liver cirrhosis at the last follow-up were censored. Multivariate Cox proportional hazard analysis was used to identify independent predictors of HCC or liver cirrhosis development. All statistical analyses were performed using SPSS version 25.0 (IBM Co., Armonk, NY, USA). Statistical significance was set at P <0.05.

Baseline characteristics

A total of 3,253 patients who were anti-HCV positive and presented to Gangnam Severance Hospital were evaluated between 2005 and 2020. Of these, 1,177 (36.2%) underwent HCV RNA testing for confirmation, with 858 (72.9%) positive for HCV RNA. A total of 319 patients with anti-HCV negative results underwent RIBA testing. A total of 132 (41.4%) tested positive, 181 (56.7%) tested negative, and 86 (1.9%) were indeterminate (Fig. 1).

The baseline characteristics of patients with chronic hepatitis C treated with antiviral treatment (n = 494) are shown in Table 1. The proportion of males was 42.5% (n = 210), and the proportion of HCV genotype was 58.5% (n = 289) for type 1, 38.9% (n = 192) for type 2, and 2.4% (n = 12) for type 3 (n = 12). The mean HCV RNA value was 6.0 log IU/mL, and the mean aspartate aminotransferase and alanine transaminase values were 66.8 and 70.5 IU/L, respectively. The proportions of patients with liver cirrhosis, HCC, diabetes, hypertension, and hepatitis B virus coinfection at baseline were 20.9% (n = 103), 1.2% (n = 6), 23.7% (n = 117), 30.2% (n = 149), and 3.2% (n = 16), respectively (Table 1).

Table 1

Baseline characteristics of chronic hepatitis C patients treated with antiviral agents
Variables	Antiviral therapy (n = 494, %)
Male (%)	210 (42.5)
Genotype
1	289 (58.5)
2	192 (38.9)
3	12 (2.4)
HCV RNA (log₁₀IU/mL)	6.0 ± 0.9
AST (IU/L)	66.8 ± 51.9
ALT (IU/L)	70.5 ± 73.9
Total bilirubin (mg/dL)	0.8 ± 0.5
Albumin (g/dL)	4.2 ± 0.5
Prothrombin time (INR)	1.07 ± 0.19
Platelet (×10³/mm³)	191 ± 75
BMI (kg/m²)	23 ± 3.5
Liver stiffness (Kpa)	11.8 ± 9.5
Controlled attenuation parameter (dB/m)	226.3 ± 40.0
Antiviral agents
Pegylated interferon plus ribavirin (%)	212 (42.9)
Daclatasvir/asunaprevir (%)	90 (18.2)
Ledipasvir/sofosbuvir (%)	48 (9.7)
Sofosbuvir and ribavirin	62 (12.6)
Elbasvir/grazoprevir	39 (7.9)
Ombitasvir/paritaprevir/ritonavir	3 (0.6)
Glecaprevir/pibrentasvir	40 (8.1)
Liver cirrhosis (%)	103 (20.9)
HCC (%)	6 (1.2)
Diabetes (%)	117 (23.7)
Hypertension (%)	149 (30.2)
HBV coinfection (%)	16 (3.2)
Variables are expressed as the mean ± SD or n (%).
HCV, hepatitis C virus; BMI, body mass index; HBV, hepatitis B virus; AST, aspartate aminotransferase; ALT, alanine transaminase; HCC, hepatocellular carcinoma

Progress According To Treatment Options

Of the 858 HCV RNA positive patients, 494 (57.6%) received first-line antiviral treatment, and of these, 443 (89.7%) experienced SVR. Specifically, 212 (42.9%) underwent pegylated interferon plus ribavirin, and 184 (86.8%) experienced SVR₂₄. Ninety (18.25%) patients who underwent daclatasvir/asunaprevir and 83 (92.2%) patients experienced SVR₁₂. Among 48 (9.7%) patients treated with ledipasvir/sofosbuvir, 45 (93.8%) experienced SVR₁₂. Among 62 (12.6%) patients who were treated with sofosbuvir and ribavirin, 54 (87.1%) experienced SVR₁₂. Among 39 (7.9%) patients treated with elbasvir/grazoprevir, 36 (92.3%) experienced SVR₁₂. Among three (0.6%) patients treated with ombitasvir/paritaprevir/ritonavir, three (100%) experienced SVR₁₂. Among 40 (8.1%) patients treated with glecaprevir/pibrentasvir, 38 (95%) experienced SVR₁₂ (Supplementary Fig. 1).

Cumulative Incidence Of Hepatocellular Carcinoma And Liver Cirrhosis

Among the 421 patients who were followed up for more than 6 months, excluding those with HCC at baseline or who developed HCC within 6 months of starting HCV treatment, 16 developed HCC. The cumulative incidence of HCC at 15 years was 14.2% at the end of treatment. Of the 16 patients, ten (62.5%) had liver cirrhosis at baseline. A total of 341 patients who had no cirrhosis before treatment were followed up for more than 6 months, and 24 new cases of cirrhosis developed. The cumulative incidence of liver cirrhosis at 15 years was 15.9% (Fig. 2).

The cumulative incidence of HCC according to SVR₁₂ was analyzed. Among the 388 patients with SVR₁₂, 14 developed HCC, with a cumulative incidence rate of 13% at 15 years. In patients without SVR₁₂, HCC occurred in two out of 33 patients at 8 years. There was no statistically significant difference in the cumulative incidence rates between the two groups (p = 0.084). The cumulative incidence of liver cirrhosis according to SVR₁₂ was also investigated. Among the 319 patients with SVR₁₂, 21 developed cirrhosis, with a cumulative incidence rate of 15% at 15 years. In patients without SVR₁₂, HCC occurred in three out of 22 patients at 8 years. There was no statistically significant difference in the cumulative incidence rate between the two groups (p = 0.051) (Fig. 3).

The cumulative incidence of HCC according to baseline liver cirrhosis was also analyzed. HCC occurred in six out of 338 patients without cirrhosis, showing a cumulative incidence rate of 10.8% at 15 years, and in ten out of 83 patients with cirrhosis, showing a cumulative incidence rate of 29.5% at 13 years. There was a statistically significant difference in the cumulative incidence between the two groups (P < 0.001) (Fig. 4).

The World Health Organization(WHO)’s 2030 global elimination goals for HCV are that 80% of eligible patients are treated, along with a 90% reduction in the incidence of new infections and a 65% reduction in liver-related mortality.⁹ However, approximately 400,000 deaths occur annually owing to liver failure and HCC due to chronic HCV infection (currently estimated to be 71 million people worldwide). An estimated 1.75 million people each year are burdened with the disease owing to new HCV infection.¹⁰

With the introduction of DAAs, the goal of hepatitis C elimination has become more attainable.² It is paramount to establish an initial screening and treatment program because HCC may occur depending on whether advanced fibrosis (F3) is present at the time of DAA treatment.¹¹ Efforts in each country to establish screening and treatment for HCV elimination are continuing every year. For example, in April 2015, Georgia, a region with a high prevalence of hepatitis C virus infection, launched the world’s first HCV elimination program to reduce the prevalence of HCV by 90% by 2020 with technical assistance from the Centers for Disease Control and Prevention.¹² Egypt implemented an effective model for HCV screening and treatment delivery in recent years. Between 2014 and 2017, the Egyptian National Committee for Control of Viral Hepatitis provided free DAA-based HCV treatment to more than two million people. As the number of patients with HCV declined in 2018, the Commission introduced a national HCV screening pilot rather than continuing DAAs treatment.^{13, 14} On the other hand, in Korea, where the prevalence is low compared to regions with high prevalence, such as Georgia and Egypt, awareness of chronic hepatitis C is low.

Our study had several clinical implications. First, this study assumes significance in that we comprehensively evaluated the number of anti-HCV positive patients who were confirmed and treated at a tertiary medical institution in South Korea. South Korea has not yet implemented a national hepatitis C elimination program. Amongst the anti-HCV positive people included in the current study (3,253), only 1,177 (36.2%) underwent HCV RNA testing for HCV confirmation (Fig. 1). This ratio is considerably lower than that of approximately 67.3% of anti-HCV positive patients in Egypt from October 2018 to September 2019.^{9, 15} The first reason for these results is that the primary purpose of HCV antibody screening was not to eliminate chronic hepatitis C. In Egypt, as the number of patients with chronic hepatitis C decreased because of the introduction of DAAs, the government conducted HCV antibody testing in early 2018 with the aim of reducing costs and eliminating chronic hepatitis C.^{9, 15} In our hospital, except for patients with risk factors for hepatitis C, HCV antibody tests were performed for routine examination before surgery or for a personal check-up. The second reason for less number of people receiving HCV RNA testing is the lack of understanding of the pathophysiology of chronic hepatitis C and the HCV treatment processes. In most cases, anti-HCV positive results were found incidentally during screening for other purposes, and not in the acute HCV infection state without any symptom. Thus, patients are likely to be unaware of the need for HCV RNA testing and follow-up for treatment. Among patients with HCV infection confirmed by HCV RNA, the proportion of patients who received treatment was 57.6%, lower than that in Egypt. This may be owing to the cost of chronic hepatitis C treatment itself and a lack of understanding of the hepatitis C treatment process and prognosis.

Second, the cumulative incidence of HCC and liver cirrhosis showed that liver cirrhosis at the time of diagnosis of chronic hepatitis C was more statistically significant than whether SVR₁₂ was reached (Fig. 2,3,4). These results are consistent with the results of previous reports.^16–20 It is clear that persistent HCV infection is the strongest factor for HCC in that it induces fibrosis progression and cirrhosis because HCV could induce carcinogenesis indirectly through inflammatory responses or directly via its transcripts or proteins.^{21, 22} However, some residual HCC risk could persist after HCV eradication, because HCV-related epigenetic changes and monoclonal micronodules that occur before SVR₁₂ are maintained indefinitely even after SVR₁₂.²³ Second, residual fibrosis may progress to advanced fibrosis or cirrhosis owing to other hepatotoxic injury sources (e.g., alcohol, drug, non-alcoholic steatohepatitis).¹¹ Therefore, it is necessary to continue HCC surveillance even after reaching SVR₁₂ in patients with advanced fibrosis or cirrhosis.

Our study has several limitations. First, this study does not specifically suggest which group to perform the HCV antibody test on as a screening test from a cost-effective point of view. Since the treatment of chronic hepatitis C reduces the risk of HCC and cirrhosis, it is evident that a national screening project to raise people’s awareness should be implemented. However, this study has a drawback in that we did not examine whether screening tests should be performed for all people or only certain groups. Second, this study showed that HCC and liver cirrhosis risk existed even in patients who achieved SVR but did not provide more specific risk stratification for HCC. This is thought to be because our study was conducted over a wide period, from the early days of interferon to the latest DAA treatments, and cirrhosis was only evaluated by abdominal ultrasound. Recently, various tools have been developed to predict HCC risk after SVR, from elastography²⁰ that can specifically measure the degree of fibrosis to deep learning HCC risk prediction models that use age, sex, race, HCV genotype, and 24 laboratory tests.²⁴ The HCC surveillance strategy of patients who have reached SVR₁₂ requires the introduction of a more specific and easy-to-use model.

In conclusion, owing to the introduction of DAA, a high SVR₁₂ of chronic hepatitis C was achieved overall, but the proportion of anti-HCV positive patients who received HCV RNA testing and treatment was not high at our tertiary medical institution. This is related to an overall lack of awareness of the purpose and necessity of the HCV screening test and chronic hepatitis C treatment process. Ultimately, it appears that a national screening project should be implemented. Our study shows that by using a public health approach, the care cascade can be greatly improved, and more patients who are anti-HCV positive can be diagnosed and treated with DAAs. For patients with chronic hepatitis C accompanied by baseline cirrhosis, HCC surveillance after SVR₁₂ is recommended, and an efficient strategy based on more specific risk stratification is required.

SVR: Sustained virologic response; SVR12: Sustained virologic response rate at 12 weeks; SVR24: Sustained virologic response rate at 24 weeks; HCC: Hepatocellular carcinoma; DAAs: Direct-acting antivirals; G/P: Glecaprevir/pibrentasvir; HCV: Hepatitis C virus; RNA: Ribonucleic acid; RIBA: Recombinant immunoblot assay; DCV/ASV: Daclatasvir/asunaprevir; LED/SOF: Ledipasvir/sofosbuvir; SOF: Sofosbuvir; EBR/GZR: Elbasvir/grazoprevir; OBV/PTV/r: Ombitasvir/paritaprevir/ritonavir; US: Ultrasonography; WHO: World Health Organization

Ethics approval and consent to participate

The protocol for the current study were approved by the Yonsei University Gangnam Severance Hospital, Institutional Review Board (3-2021-0255). The need for informed consent was waived by the ethics committee/Institutional Review Board of Yonsei University Gangnam Severance Hospital, because of the retrospective nature of the study.

Consent for publish

Not applicable.

Availability of data and materials

The data used to support the findings of this study are available from the corresponding author upon request.

Competing interests

The authors declare that they have no conflicts of interest.

Funding

This study was supported by a faculty research grant from Yonsei University College of Medicine [6-2019-0091].

Authors’ contributions

HWL and JHL conceived and designed the protocol; MKim, SK, JIL, KSL collected the data; SHY wrote the manuscript; SHY and HWL analyzed the data; HWL and JHL critically revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors deeply appreciate all the patients who were involved in the present study and our team from Gangnam Severance Hospital.

Jeong SH, Jang ES, Choi HY, Kim KA, Chung W, Ki M. Current status of hepatitis C virus infection and countermeasures in South Korea. Epidemiol Health. 2017;39:e2017017. doi:10.4178/epih.e2017017
Nozaki A, Atsukawa M, Kondo C, et al. The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study. Hepatol Int. Mar 2020;14(2):225–238. doi:10.1007/s12072-020-10019-z
Sarrazin C. Treatment failure with DAA therapy: Importance of resistance. J Hepatol. Jun 2021;74(6):1472–1482. doi:10.1016/j.jhep.2021.03.004
Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. Jan 2018;67(1):358–380. doi:10.1002/hep.29086
2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver. May 15 2019;13(3):227–299. doi:10.5009/gnl19024
Yoo SH, Lim TS, Lee HW, et al. Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B. J Viral Hepat. Oct 2021;28(10):1362–1372. doi:10.1111/jvh.13560
Kim MN, Kim SU, Kim BK, et al. Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. Hepatology. Jun 2015;61(6):1851–9. doi:10.1002/hep.27735
Jeon MY, Lee HW, Kim SU, et al. Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis. Hepatol Int. May 2017;11(3):268–276. doi:10.1007/s12072-017-9789-y
Dore GJ, Bajis S. Hepatitis C virus elimination: laying the foundation for achieving 2030 targets. Nat Rev Gastroenterol Hepatol. Feb 2021;18(2):91–92. doi:10.1038/s41575-020-00392-3
Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. Sep 16 2017;390(10100):1151–1210. doi:10.1016/s0140-6736(17)32152-9
Ioannou GN. HCC surveillance after SVR in patients with F3/F4 fibrosis. J Hepatol. Feb 2021;74(2):458–465. doi:10.1016/j.jhep.2020.10.016
Mitruka K, Tsertsvadze T, Butsashvili M, et al. Launch of a Nationwide Hepatitis C Elimination Program–Georgia, April 2015. MMWR Morb Mortal Wkly Rep. Jul 24 2015;64(28):753–7. doi:10.15585/mmwr.mm6428a2
Behzadifar M, Gorji HA, Rezapour A, Bragazzi NL. Comparison of prevention, screening and treatment of hepatitis C in Iran, Egypt and Georgia. J Virus Erad. Apr 1 2019;5(2):116–121.
Guerra J, Garenne M, Mohamed MK, Fontanet A. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat. Aug 2012;19(8):560–7. doi:10.1111/j.1365-2893.2011.01576.x
Waked I, Esmat G, Elsharkawy A, et al. Screening and Treatment Program to Eliminate Hepatitis C in Egypt. N Engl J Med. Mar 19 2020;382(12):1166–1174. doi:10.1056/NEJMsr1912628
Barbara L, Benzi G, Gaiani S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology. Jul 1992;16(1):132–7. doi:10.1002/hep.1840160122
Vergniol J, Foucher J, Terrebonne E, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology. Jun 2011;140(7):1970-9, 1979.e1-3. doi:10.1053/j.gastro.2011.02.058
EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. Aug 2018;69(2):461–511. doi:10.1016/j.jhep.2018.03.026
Ioannou GN, Beste LA, Green PK, et al. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. Gastroenterology. Nov 2019;157(5):1264–1278.e4. doi:10.1053/j.gastro.2019.07.033
Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. Jun 2009;49(6):1954–61. doi:10.1002/hep.22870
Bandiera S, Billie Bian C, Hoshida Y, Baumert TF, Zeisel MB. Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma. Curr Opin Virol. Oct 2016;20:99–105. doi:10.1016/j.coviro.2016.09.010
Jeong SW, Jang JY, Chung RT. Hepatitis C virus and hepatocarcinogenesis. Clin Mol Hepatol. Dec 2012;18(4):347–56. doi:10.3350/cmh.2012.18.4.347
Paradis V, Dargere D, Bonvoust F, et al. Clonal analysis of micronodules in virus C-induced liver cirrhosis using laser capture microdissection (LCM) and HUMARA assay. Lab Invest. Oct 2000;80(10):1553–9. doi:10.1038/labinvest.3780165
Ioannou GN, Tang W, Beste LA, et al. Assessment of a Deep Learning Model to Predict Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis. JAMA Netw Open. Sep 1 2020;3(9):e2015626. doi:10.1001/jamanetworkopen.2020.15626

No competing interests reported.

FigS1.tif

Download PDF

Journal Publication

published 11 Apr, 2023

Read the published version in BMC Gastroenterology →

Editorial decision: Major revision
20 Apr, 2022
Reviews received at journal
05 Apr, 2022
Reviewers agreed at journal
05 Apr, 2022
Reviewers invited by journal
14 Mar, 2022
Editor assigned by journal
13 Mar, 2022
Editor invited by journal
10 Mar, 2022
Submission checks completed at journal
10 Mar, 2022
First submitted to journal
08 Mar, 2022

You are reading this latest preprint version

Progress and Prognosis According to the Care Cascade in Patients Who Are Anti-HCV Positive

Status:

Journal Publication

Version 1

Abstract

Background

Methods

Results

Conclusions

Figures

Background

Methods

Results

Baseline characteristics

Progress According To Treatment Options

Cumulative Incidence Of Hepatocellular Carcinoma And Liver Cirrhosis

Discussion

Conclusions

List Of Abbreviations

Declarations

References

Additional Declarations

Supplementary Files

Status:

Journal Publication

Version 1